Colombia Post-Market Compliance Calendar 2026-2027: Key Dates and Actions

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

This calendar covers the 12 months from November 2026 through October 2027. Before it begins, several decisive milestones have already passed: the final tier of the transition period in Article 15 of Resolución 1405 de 2022 expired on February 8, 2026; INVIMA confirmed on March 12, 2026 that semantic reporting is fully mandatory; Resolución 2025067543 (published December 22, 2025) was partially amended by Resolución 2026033499 (June 30, 2026); and the draft decree for the new device regime completed its WTO international notification on May 18, 2026, with the comment period closing on July 17, 2026.

GRZAN’s conclusion is that the main theme of the next 12 months is not reacting to new rules but maintaining well the obligations that have already taken effect. Semantic reporting, renewal windows, vigilance duties and ledger consistency make up the entire workload; the landing of the draft decree is the only uncertain variable, and it is more likely to reshuffle pathways than to add obligations.

2. Legal basis

RegulationNumberPublication dateProvisions
Resolución 1405 de 2022 (semantic standard and UDI-DI)Resolución 1405 de 2022August 8, 2022Art. 15 (transition period, final tier ending February 8, 2026)
Decreto 4725 de 2005 (registration, marketing authorization and health surveillance regime for medical devices)DECRETO 4725 DE 26 DE DICIEMBRE DE 2005December 26, 2005Art. 16 / Art. 17 (registration types), Art. 20 (certificate contents), Art. 29 (POA), Art. 40 (implant card)
Decreto 582 de 2017 (amending Decreto 4725 de 2005)Decreto 0582 de 2017April 4, 2017Art. 32 (automatic renewal for Class I/IIa); change, ex-post verification and suspension / cancellation rules
Decreto 3770 de 2004 (special decree for in vitro diagnostics)Decreto 3770 de 20042004Validity provisions (Categoría I / II valid 10 years, Categoría III valid 5 years)
Resolución 4816 de 2008 (national device vigilance program)Resolución 4816 de 2008200872-hour reporting of serious adverse events; quarterly periodic reports; recalls executed under INVIMA directives
Resolución 4002 de 2007 (storage and repackaging capability manual)Resolución 4002 de 20072007CCAA valid 5 years; re-inspection requested at least 5 business days before expiry
Resolución 2025067543 and Resolución 2026033499 (fee schedule and its partial amendment)Resolución 2025067543 / Resolución 2026033499December 22, 2025 / June 30, 2026Fee schedule and partial amendment provisions
Proyecto de Decreto on the Régimen Sanitario de Dispositivos MédicosDraft (approximately 16 chapters and 180 articles)January 2026UDI moved to the initial application; three-tier authorization; validity linked to post-market performance (not yet signed or published)

3. Expert insights

1. November 2026 to January 2027: closing semantic reporting gaps and re-checking fee budgets

Verify the semantic reporting status of every product on sale in SIRIS, item by item; do not schedule shipments or tenders for uncompleted products. At the same time, re-check budgets against Resolución 2025067543 as amended by Resolución 2026033499, using 321.91 UVB for Class I/IIa and 364.36 UVB for Class IIb/III. GRZAN’s judgment is that the best investment in this phase is not new projects but clearing the installed base — Chinese manufacturers hold approximately 61,000 records in the Colombian registration database (third-party statistics), and the size of that installed base dictates the order of cleanup.

2. February to April 2027: re-sorting the renewal ledger and the IVD expiry wave

The device renewal window is at least 3 months before expiry; for IVDs it is within the 6 months before expiry. Device validity is uniformly 10 years, while IVD Categoría III lasts only 5 years; the two rhythms differ and the ledgers must be kept separate. The action is to list every registration number expiring within the next 12 months and plan filing dates backward from each expiry. Schedule Class I/IIa automatic renewals on the conservative figure of about 30 days; do not plan production around the 3-business-day figure.

3. May to July 2027: the observation window for the draft decree

The draft decree completed its WTO international notification on May 18, 2026 and the comment period closed on July 17, 2026; as of the verification date it has not been signed or published, and Decreto 4725 de 2005 and Decreto 3770 de 2004 remain the laws in force. The draft’s directions include three-tier authorization, validity linked to post-market performance, ISO 13485 named explicitly as the device GMP standard, a reliance mechanism on the assessment results of foreign regulators such as the FDA, EMA and ANVISA, a unified framework for IVDs and SaMD, UDI moved to the initial application, and a self-proposed 18-month transition period. GRZAN’s position is: add no investment during the observation window, but complete two preparations — confirm where each product sits and fold the UDI-DI into master data.

4. August to October 2027: internal audit of the vigilance system and evidence retention

Audit the vigilance system internally against Resolución 4816 de 2008: the 72-hour serious adverse event reporting ledger, quarterly periodic reports and zero report records, the recall SOP and distribution records, and patient implant cards for implantable devices (Decreto 4725 de 2005, Art. 40). The value of this system shows itself in the follow-up control (Article 57 of Ley 962 de 2005, within 15 days after issuance) and in ex-post verification — whether evidence can be produced quickly at that moment depends on whether it was maintained all along.

4. Practical recommendations

  1. Registration holder (titular): complete a full verification of semantic reporting status in SIRIS from November 2026 and suspend shipment and tender plans for uncompleted products.
  2. Regulatory affairs leads: export the expiry list using a practical estimate of 3 months before expiry for devices and within 6 months for IVDs, with filing dates planned backward.
  3. Finance and commercial teams: build the 2027 budget at the current rates of Resolución 2025067543 / 2026033499.
  4. Regulatory affairs leads: schedule Class I/IIa automatic renewals on the conservative figure of about 30 days; do not adopt the 3-business-day figure.
  5. Chinese manufacturers: confirm where each product sits in the draft’s three-tier authorization structure and fold the UDI-DI into product master data.
  6. Vigilance responsible person: operate the 72-hour reporting countdown ledger and the quarterly periodic reporting mechanism, including a zero-report process.

5. Verification checklist

  • □ The semantic reporting status of all products on sale has been verified and uncompleted products suspended from shipment and tender
  • □ The expiry list for the next 12 months has been exported, with devices and IVDs managed in separate ledgers
  • □ Class I/IIa automatic renewals are scheduled on the conservative figure of about 30 days
  • □ The 2027 budget has been built at the current rates
  • □ Each product’s place in the draft’s three-tier authorization structure has been confirmed and the UDI-DI folded into master data
  • □ The 72-hour reporting ledger and the quarterly periodic reporting mechanism are operating

Regulatory information verified as of October 29, 2026

All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.

— GRZAN Regulatory Team

GRZAN keeps device manufacturers compliant on the Colombian market across the whole post-market cycle: technovigilance and adverse event reporting, recalls and field corrective actions, follow-up control and inspection response, renewals and changes in SIRIS, and forward planning against the incoming decree. To put this calendar into an executable plan, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail